The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | Transplantation in modern myeloma therapeutics
The need for transplantation in myeloma is frequently a topic of interest when discussing the most effective treatment options, due to the increased availability of novel therapeutics. Here, Mohamad Mohty, MD, PhD, University Pierre & Marie Curie, Paris, France is joined with Philip McCarthy, MD, of University at Buffalo, Buffalo, NY, Andrew Spencer, MBBS, FRACP FRCPA, DM, of Alfred Hospital, Monash University, Melbourne, Australia, and David Siegel, MD, PhD, of the John Theurer Cancer Center, Hackensack, NJ, to debate whether transplantation is still relevant in today’s clinical practice.
